NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

NCT06621329

RecruitingPhase 2, Phase 3

Sponsor: University of California, Davis

Conditions: SAH (Subarachnoid Hemorrhage), Headache

Interventions: Transnasal sphenopalatine ganglion block

Countries: United States

The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Acute subarachnoid hemorrhage
* Age greater than 18 years
* Secured aneurysm
* Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision
* maker
* Patient or surrogate decision maker is available to consent

Exclusion Criteria:

* Less than 18 years old
* Unsecured aneurysm
* Pregnant or lactating
* Prisoner
* Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker
* Nasal or facial trauma or surgery within the last three months
* Allergy to lidocaine, bupivacaine, or dexamethasone
* Patient is unable to consent and no available surrogate decision maker
Locations (1)
  • Sacramento, California, United States